NCT01762774 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 16, 2013

Primary Completion Date

May 1, 2014

Study Completion Date

May 1, 2014

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK2256294

GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.

DRUG

Placebo

Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge